Peptide Blends

Sermorelin & Ipamorelin Blend

A research blend combining sermorelin (GHRH analogue) with ipamorelin (GHS-R1a agonist) for synergistic GH release via complementary mechanisms.

C121H200N42O30 / C38H49N9O5Half-life: Sermorelin: ~20 min; Ipamorelin: ~2 hours

Community Rating

No ratings yet

⚠ Research & Educational Use Only. Sermorelin & Ipamorelin Blend is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.

Medically reviewed by Dr. Amanda Haslett, MBChB MRCGPWritten by the KnowYourPeptide Research TeamLast updated April 2026
Our editorial standards →
Key Takeaways
  • Synergistic GH release exceeding either peptide alone
  • Selective GHS action with minimal cortisol or prolactin elevation
  • Preserves physiological GH pulsatility
  • Sermorelin & Ipamorelin Blend is not FDA-approved for human use. It is a research chemical for scientific study only.

Research At a Glance

  • Synergistic GH release exceeding either peptide alone
  • Selective GHS action with minimal cortisol or prolactin elevation
  • Preserves physiological GH pulsatility
  • Supports lean mass and fat reduction in research models

What is Sermorelin & Ipamorelin Blend?

Tap any underlined term for an instant definition.

Sermorelin & Ipamorelin Blend is a pre-formulated research preparation combining two distinct growth hormone-stimulating peptides: sermorelin (a analogue) and ipamorelin (a ghrelin-mimetic GHS). The combination produces synergistic GH release through complementary receptor mechanisms, with research showing a 3-4 fold amplification vs either peptide alone.

What It Is

  • Sermorelin ( 1-29): activates GHRHR on pituitary somatotrophs, driving cAMP-mediated GH release
  • Ipamorelin: binds GHS-R1a on pituitary somatotrophs and suppresses hypothalamic somatostatin
  • Combined in a single vial for convenience; both peptides are co-administered subcutaneously
  • Ipamorelin selected for its high GH selectivity (minimal cortisol or prolactin elevation vs other GHSPs)

How It Works

  • Sermorelin presses the "accelerator" via GHRHR activation
  • Ipamorelin simultaneously releases the "brake" (somatostatin suppression) + adds its own direct GH-stimulating effect
  • Result: GH pulse amplitude 3-4x greater than either peptide alone in matched animal studies
  • increases 60-80% above baseline with 3-month daily administration in body composition studies

Key Research Findings

  • Body composition: 12-week daily administration in research subjects showed lean mass increases of 2.5-3 kg and fat mass reduction of 2-3%
  • : Increased 60-78% from baseline at 3 months
  • Sleep: Improved slow-wave sleep duration, creating positive GH feedback (better sleep = more GH)
  • Selectivity: Cortisol and prolactin remain within normal range throughout treatment course

Dosing From the Literature

  • Sermorelin 200-300 mcg + Ipamorelin 200-300 mcg per injection
  • Once daily at bedtime (preferred) or twice daily
  • Administered subcutaneous, on empty stomach

Storage and Handling

  • Lyophilised: 2-8 degrees C; 24 months
  • : 2-8 degrees C; use within 30 days
  • Do not mix with other peptides in the same syringe unless specified by protocol

Key Research Benefits

Documented effects observed in preclinical and clinical studies on Sermorelin & Ipamorelin Blend. See all Peptide Blends peptides for comparison.

Synergistic GH release exceeding either peptide alone
Selective GHS action with minimal cortisol or prolactin elevation
Preserves physiological GH pulsatility
Supports lean mass and fat reduction in research models

Side Effects & Risks

Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →

Dosing Data from the Literature

Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.

Research Dosing Protocol

Typical research blend: sermorelin 200-300 mcg + ipamorelin 200-300 mcg per administration. Once daily at bedtime or twice daily.

Enter your vial size and target dose to get the exact injection volume.

Administration in Research Settings

Standard reconstitution and administration methodology for laboratory research use.

and administered by . Best given on an empty stomach at bedtime.

Explore Further

Quick Reference

Half-Life
Sermorelin: ~20 min; Ipamorelin: ~2 hours
Formula
C121H200N42O30 / C38H49N9O5
Legal Status
Research chemicals. Not approved for human use by FDA.
Storage
Lyophilised blend: 2-8 degrees C. Reconstituted: 2-8 degrees C; use within 30 days.

Research Use Only

This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.

AI Peptide Advisor

online · Claude + Gemini
ask your question...